What is the share price of Jeena Sikho Lifecare Ltd (JSLL) today?
The share price of JSLL as on 5th December 2025 is ₹684.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Jeena Sikho Lifecare Ltd (JSLL) share?
The past returns of Jeena Sikho Lifecare Ltd (JSLL) share are- Past 1 week: -4.68%
- Past 1 month: -11.48%
- Past 3 months: -11.13%
- Past 6 months: 54.29%
- Past 1 year: 53.53%
- Past 3 years: 2157.17%
- Past 5 years: 3454.52%
What are the peers or stocks similar to Jeena Sikho Lifecare Ltd (JSLL)?
The peers or stocks similar to Jeena Sikho Lifecare Ltd (JSLL) include:What is the dividend yield % of Jeena Sikho Lifecare Ltd (JSLL) share?
The current dividend yield of Jeena Sikho Lifecare Ltd (JSLL) is 0.16.What is the market cap of Jeena Sikho Lifecare Ltd (JSLL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jeena Sikho Lifecare Ltd (JSLL) is ₹8509.63 Cr as of 5th December 2025.What is the 52 week high and low of Jeena Sikho Lifecare Ltd (JSLL) share?
The 52-week high of Jeena Sikho Lifecare Ltd (JSLL) is ₹849.50 and the 52-week low is ₹280.What is the PE and PB ratio of Jeena Sikho Lifecare Ltd (JSLL) stock?
The P/E (price-to-earnings) ratio of Jeena Sikho Lifecare Ltd (JSLL) is 93.79. The P/B (price-to-book) ratio is 31.17.Which sector does Jeena Sikho Lifecare Ltd (JSLL) belong to?
Jeena Sikho Lifecare Ltd (JSLL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Jeena Sikho Lifecare Ltd (JSLL) shares?
You can directly buy Jeena Sikho Lifecare Ltd (JSLL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Jeena Sikho Lifecare Ltd
JSLL Share Price
684.602.09% (-14.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
JSLL Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
JSLL Performance & Key Metrics
JSLL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 57.77 | 31.17 | 0.16% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
100%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
JSLL Company Profile
Jeena Sikho Lifecare is engaged in developing health care products and providing ayurvedic healthcare services in India.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
JSLL Sentiment Analysis
JSLL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
JSLL Stock Summary · November 2025
The company is experiencing robust financial growth, with a significant year-on-year revenue increase of 66% and a profit after tax rise of 121%, driven by strategic partnerships and an expanding product line. While operational efficiency is being enhanced through new software and increased bed capacity, challenges such as occupancy rates and government payment delays remain critical. The focus on preventive healthcare and wellness services, alongside a cautious approach to capital allocation, reflects a commitment to sustainable growth. Additionally, international operations are proving profitable, and innovative customer engagement strategies, including a referral system, are expected to further boost patient admissions and overall market presence.
JSLL Stock Growth Drivers
JSLL Stock Growth Drivers
8Significant Financial Growth
In Q2 FY’26, the company reported a revenue increase of 66% year-on-year, reaching Rs. 190
Expansion of Healthcare Services
The company has expanded its service footprint by adding 582 beds, bringing the total to
JSLL Stock Challenges
JSLL Stock Challenges
4Occupancy and Revenue Concerns
The company is facing challenges with low occupancy rates, which are not at full capacity
Partnership and Expansion Challenges
The company has encountered bureaucratic hurdles in establishing partnerships with government colleges, which has led
JSLL Forecast
JSLL Forecasts
Price
Revenue
Earnings
JSLL Share Price Forecast
JSLL Share Price Forecast
2025
Current
₹684.60
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹684.60
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
JSLL Company Revenue Forecast
JSLL Company Revenue Forecast
2025
Current
₹475.48
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹475.48
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
JSLL Stock EPS (Earnings Per Share) Forecast
JSLL Stock EPS (Earnings Per Share) Forecast
2025
Current
₹7.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹7.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
JSLL
JSLL
Income
Balance Sheet
Cash Flow
Annual Normal View
JSLL Income Statement
JSLL Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 105.88 | 95.18 | 136.88 | 147.94 | 206.18 | 330.85 | 475.48 | 622.23 | ||||||||
Raw Materials | 32.73 | 10.15 | 15.01 | 11.94 | 15.48 | 24.84 | 35.70 | 372.55 | ||||||||
| Power & Fuel Cost | 0.68 | 0.76 | 1.11 | 1.07 | 2.35 | 4.76 | 8.63 | |||||||||
| Employee Cost | 14.45 | 21.65 | 30.38 | 33.75 | 43.44 | 65.91 | 100.49 | |||||||||
| Selling & Administrative Expenses | 56.95 | 48.08 | 69.56 | 75.96 | 85.23 | 123.33 | 177.06 | |||||||||
| Operating & Other expenses | -9.61 | 3.23 | 2.81 | 5.57 | 11.07 | 12.56 | 21.85 | |||||||||
EBITDA | 10.68 | 11.31 | 18.01 | 19.65 | 48.61 | 99.45 | 131.75 | 249.68 | ||||||||
| Depreciation/Amortization | 1.21 | 1.94 | 2.46 | 3.31 | 3.13 | 5.10 | 8.71 | 37.63 | ||||||||
| PBIT | 9.47 | 9.37 | 15.55 | 16.34 | 45.48 | 94.35 | 123.04 | 212.05 | ||||||||
| Interest & Other Items | 1.15 | 1.64 | 1.36 | 1.18 | 0.95 | 0.43 | 0.97 | 13.65 | ||||||||
| PBT | 8.32 | 7.73 | 14.19 | 15.16 | 44.53 | 93.92 | 122.07 | 198.40 | ||||||||
| Taxes & Other Items | 2.33 | 1.99 | 3.89 | 3.89 | 10.78 | 24.71 | 31.34 | 51.11 | ||||||||
| Net Income | 5.99 | 5.74 | 10.30 | 11.27 | 33.75 | 69.21 | 90.73 | 147.29 | ||||||||
| EPS | 0.41 | 0.39 | 0.70 | 0.72 | 2.34 | 5.57 | 7.30 | 11.85 | ||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.96 | 1.09 | 1.10 | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.17 | 0.15 | 0.09 |
JSLL Company Updates
JSLL Stock Peers
JSLL Past Performance & Peer Comparison
JSLL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Jeena Sikho Lifecare Ltd | 93.79 | 31.17 | 0.16% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
JSLL Stock Price Comparison
Compare JSLL with any stock or ETFCompare JSLL with any stock or ETF
JSLL
JSLL Holdings
JSLL Shareholdings
JSLL Promoter Holdings Trend
JSLL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
JSLL Institutional Holdings Trend
JSLL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
JSLL Shareholding Pattern
JSLL Shareholding Pattern
JSLL Shareholding History
JSLL Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing JSLL stock
smallcases containing JSLL stock
Looks like this stock is not in any smallcase yet.
JSLL Events
JSLL Events
JSLL Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
JSLL Dividend Trend
No dividend trend available
JSLL Upcoming Dividends
JSLL Upcoming Dividends
No upcoming dividends are available
JSLL Past Dividends
JSLL Past Dividends
Cash Dividend
Ex DateEx DateSep 22, 2025
Final
Final | Div/Share: ₹1.10
Dividend/Share
₹1.10
Ex DateEx Date
Sep 22, 2025
Cash Dividend
Ex DateEx DateAug 20, 2024
Final
Final | Div/Share: ₹4.18
Dividend/Share
₹4.18
Ex DateEx Date
Aug 20, 2024
Cash Dividend
Ex DateEx DateAug 25, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 25, 2023
JSLL Stock News & Opinions
JSLL Stock News & Opinions
Articles & Videos
Earnings
Jeena Sikho Lifecare standalone net profit rises 121.02% in the September 2025 quarter
Net profit of Jeena Sikho Lifecare rose 121.02% to Rs 58.79 crore in the quarter ended September 2025 as against Rs 26.60 crore during the previous quarter ended September 2024. Sales rose 66.40% to Rs 189.85 crore in the quarter ended September 2025 as against Rs 114.09 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales189.85114.09 66 OPM %48.5035.31 - PBDT89.1641.66 114 PBT78.7635.41 122 NP58.7926.60 121 Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Jeena Sikho Lifecare to discuss results
Jeena Sikho Lifecare will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Jeena Sikho Lifecare commences operations of 230-bed hospital in Maharashtra
Jeena Sikho Lifecare has commenced operations of its 230-bed hospital at Raigad District, Maharashtra with effect from 23 September 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare conducts clinical trials for four products
Jeena Sikho Lifecare has received approval for conducting a clinical trial on the following products: 1. Anti-Diabetes Efficacy of SDM02 Tablets - Pre-clinical study conducted at MIET, Meerut, on streptozotocin-induced diabetic rats. The tablets were found effective with no mortality or adverse effects at the tested dose. 2. Shuddhi XS Syrup - Clinical trial on 60 subjects with constipation conducted at CCFT Laboratories, Meerut. 92% reported relief in constipation and abdominal pain, with no adverse events. 3. Petshuddhi Churna - Retrospective clinical study on 100 patient records conducted at Hospital & Institute of Integrated Medical Sciences, Meerut. Significant improvement observed in bowel movement, stool consistency, and abdominal discomfort. No adverse events reported. 4. Shuddhi Dr. B P Care Tablets - Clinical trial on 60 hypertensive patients conducted at CCFT Laboratories, Meerut. Significant reduction in systolic and diastolic blood pressure and heart rate was observed within 2-3 hours and sustained for 6 hours. No adverse events reported. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare AGM scheduled
Jeena Sikho Lifecare announced that the Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare announces board meeting date
Jeena Sikho Lifecare will hold a meeting of the Board of Directors of the Company on 27 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Jeena Sikho Lifecare standalone net profit rises 217.91% in the June 2025 quarter
Net profit of Jeena Sikho Lifecare rose 217.91% to Rs 51.31 crore in the quarter ended June 2025 as against Rs 16.14 crore during the previous quarter ended June 2024. Sales rose 74.22% to Rs 174.29 crore in the quarter ended June 2025 as against Rs 100.04 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales174.29100.04 74 OPM %45.2124.64 - PBDT78.2026.35 197 PBT68.5521.07 225 NP51.3116.14 218 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare to discuss results
Jeena Sikho Lifecare will hold a meeting of the Board of Directors of the Company on 14 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare revises Final Dividend
Jeena Sikho Lifecare post effectiveness of the split/ sub-division of every 1 (One) equity share of the Company of the face value of Rs. 10/- each into 5 (Five) equity shares of the face value of Rs. 2/- each, with effect from June 12, 2025, the amount of final dividend now stands at Rs.1.10 per equity share of Rs.2 each. The Dividend earlier declared on 16 May 2025 was Rs.5.47 per equity share of face value of Rs.10 each.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Board of Jeena Sikho Lifecare recommends final dividend
Jeena Sikho Lifecare announced that the Board of Directors of the Company at its meeting held on 16 May 2025, inter alia, have recommended the final dividend of Rs 5.47 per equity Share (i.e. 54.7%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 37.95%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.04% to 0.11%
Over the last 5 years, net income has grown at a yearly rate of 73.69%, vs industry avg of 20.02%